Oxford Cancer Analytics, an Oxford, UK- and Toronto, Canada-based medtech company developing blood tests for early cancer detection using proteomics and AI, raised USD$11M in Series A funding.
The round was led by We Venture Capital and Cross-Border Impact Ventures with participation from return investors Eka Ventures, and Civilization Ventures, and new investors DigitalDx Ventures, Macmillan Cancer Support, Aurelium Ventures, OKG Capital, and angel investors.
The company intends to use the funds to develop and globally commercialize its new generation of minimally invasive liquid biopsy blood tests for the early detection of lung cancer.
Oxford Cancer Analytics (OXcan) is developing a new generation of liquid biopsy blood tests using proteomics and explainable machine learning approaches that can detect the deadliest cancers early, when they can still be cured.
This blood test can be conducted in a minimally invasive, and routine manner with superior accuracy and localization capacity in large populations. The company has applied their biomarker discovery and validation platform starting from lung cancer, the leading cause of cancer mortality worldwide, and achieved ISO13485 certification status.
OXcan has also appointed Dr. Heinrich Roder as Senior Vice President, Research & Development.
FinSMEs
09/01/2025